{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:32:35Z","timestamp":1788942755327,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.04.026","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:03:08Z","timestamp":1780372988000},"page":"557-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["In Utero Gene Therapy for Sickle Cell Disease: Current Evidence, Ethical Considerations, and Future Directions\u2014A Scoping Review"],"prefix":"10.1016","volume":"48","author":[{"given":"Efe","family":"Cudjoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Thorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneka","family":"Molokwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clinthera.2026.04.026_bib0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment","volume":"5","author":"Inusa","year":"2019","journal-title":"Int J Neonatal Screen"},{"issue":"5","key":"10.1016\/j.clinthera.2026.04.026_bib0002","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.25443","article-title":"Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients","volume":"94","author":"Rab","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clinthera.2026.04.026_bib0003","doi-asserted-by":"crossref","first-page":"B9","DOI":"10.1016\/j.ajog.2021.09.001","article-title":"Society for maternal-fetal medicine special statement: beyond the scalpel: in utero fetal gene therapy and curative medicine","volume":"225","author":"Shanahan","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0004","unstructured":"World Health Organization. Sickle-cell disease. WHO Newsroom. 2025. Accessed October 11, 2025. Https:\/\/Www.Who.Int\/News-Room\/Fact-Sheets\/Detail\/Sickle-Cell-Disease."},{"issue":"21","key":"10.1016\/j.clinthera.2026.04.026_bib0005","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.3390\/jcm13216404","article-title":"The current role of hydroxyurea in the treatment of sickle cell anemia","volume":"13","author":"L\u00f3pez Rubio","year":"2024","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.clinthera.2026.04.026_bib0006","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clinthera.2026.04.026_bib0007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40291-020-00445-y","article-title":"The future of in utero gene therapy","volume":"24","author":"Peranteau","year":"2020","journal-title":"Mol Diagn Ther"},{"issue":"17","key":"10.1016\/j.clinthera.2026.04.026_bib0010","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.omtm.2021.09.010","article-title":"CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease","volume":"23","author":"Demirci","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"24","key":"10.1016\/j.clinthera.2026.04.026_bib0024","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1182\/bloodadvances.2025016775","article-title":"In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs","volume":"9","author":"Karimzadeh","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clinthera.2026.04.026_bib0011","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s12033-024-01155-0","article-title":"Detection of CRISPR\/Cas9-mediated fetal hemoglobin reactivation in erythroblasts derived from cord blood-hematopoietic stem cells","volume":"67","author":"Maroofi","year":"2025","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0009","doi-asserted-by":"crossref","unstructured":"Klatt, D, Liu, B-Y, Mucci, A, et al. (2025). In vivo HSC gene therapy using BaEVRLess-Pseudotyped alpha-retroviral and lentiviral vectors. 10.2139\/ssrn.5194965.","DOI":"10.2139\/ssrn.5194965"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0023","doi-asserted-by":"crossref","unstructured":"Xu S., Liang D., Wang Q., et al. In vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery. bioRxiv. Published online January 1, 2024:2024.10.28.620445. doi:10.1101\/2024.10.28.620445.","DOI":"10.1101\/2024.10.28.620445"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0008","doi-asserted-by":"crossref","unstructured":"Fontana L., Martinucci P., Amistadi S., et al. Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease. Cell Rep Med. doi:10.1016\/j.xcrm.2025.102376.","DOI":"10.1016\/j.xcrm.2025.102376"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0034","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-204091","article-title":"CRISPR Cas-9 editing for treating sickle cell disease: a systematic review and meta-analysis","volume":"144","author":"Desai","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinthera.2026.04.026_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103060","article-title":"CRISPR\/Cas9 gene editing for curing sickle cell disease","volume":"60","author":"Park","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"10.1016\/j.clinthera.2026.04.026_bib0012","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat Med"},{"issue":"32","key":"10.1016\/j.clinthera.2026.04.026_bib0018","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2400783121","article-title":"In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells","volume":"121","author":"Palanki","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0019","doi-asserted-by":"crossref","unstructured":"Worthington A.K., Borges B., Lum T., et al. In utero lipid nanoparticle delivery achieves robust editing in hematopoietic stem cells. bioRxiv. Published online January 1, 2025:2025.05.12.652147. doi:10.1101\/2025.05.12.652147.","DOI":"10.1101\/2025.05.12.652147"},{"issue":"488","key":"10.1016\/j.clinthera.2026.04.026_bib0020","doi-asserted-by":"crossref","first-page":"eaav8375","DOI":"10.1126\/scitranslmed.aav8375","article-title":"In utero gene editing for monogenic lung disease","volume":"11","author":"Alapati","year":"2019","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.clinthera.2026.04.026_bib0022","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/bloodadvances.2023012247","article-title":"Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation","volume":"8","author":"Riley","year":"2024","journal-title":"Blood Adv"},{"issue":"140","key":"10.1016\/j.clinthera.2026.04.026_bib0021","doi-asserted-by":"crossref","DOI":"10.3791\/58047","article-title":"Intravenous and intra-amniotic in utero transplantation in the murine model","author":"Ahn","year":"2018","journal-title":"J Vis Exp"},{"issue":"11","key":"10.1016\/j.clinthera.2026.04.026_bib0035","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jama.1997.03550110070039","article-title":"In utero hematopoietic stem cell transplantation: a status report","volume":"278","author":"Flake","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fphar.2014.00270","article-title":"In utero therapy for congenital disorders using amniotic fluid stem cells","volume":"5","author":"Ramachandra","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.58","article-title":"CRISPR-Cas9 for in vivo gene therapy: promise and hurdles","volume":"5","author":"Dai","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.clinthera.2026.04.026_bib0026","first-page":"56","article-title":"Stem cell and genetic therapies for the fetus","volume":"22","author":"Pearson","year":"2013","journal-title":"Fetal Surg Curr Status"},{"issue":"6","key":"10.1016\/j.clinthera.2026.04.026_bib0016","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.siny.2017.05.003","article-title":"Fetal stem cell and gene therapy","volume":"22","author":"Witt","year":"2017","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.20","article-title":"In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application","volume":"3","author":"Almeida-Porada","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.clinthera.2026.04.026_bib0037","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymthe.2019.02.015","article-title":"In utero gene therapy consensus statement from the IFeTIS","volume":"27","author":"Almeida-Porada","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinthera.2026.04.026_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.624477","article-title":"In utero Therapy for the treatment of sickle cell disease: taking advantage of the fetal immune system","volume":"8","author":"Cortabarria","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.clinthera.2026.04.026_bib0017","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.ymthe.2025.03.016","article-title":"Current and future treatments for sickle cell disease: from hematopoietic stem cell transplantation to in vivo gene therapy","volume":"33","author":"Ball","year":"2025","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.clinthera.2026.04.026_bib0025","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s12033-024-01155-0","article-title":"Detection of CRISPR\/Cas9-mediated fetal hemoglobin reactivation in erythroblasts derived from cord blood-hematopoietic stem cells","volume":"67","author":"Maroofi","year":"2025","journal-title":"Mol Biotechnol"},{"issue":"8","key":"10.1016\/j.clinthera.2026.04.026_fur1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2105\/AJPH.2023.307315","article-title":"CRISPR in public health: the health equity implications and role of community in gene-editing research and applications","volume":"113","author":"Subica","year":"2023","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.clinthera.2026.04.026_fur2","first-page":"S434","article-title":"817 Trans-placental transport of a novel fluorescent lipid nanoparticle in a pre-clinical fetal therapy murine model","volume":"230","author":"Zietsman","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clinthera.2026.04.026_fur3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/bloodadvances.2023010354","article-title":"In utero hematopoietic cell transplantation leads to sustained engraftment in a mouse model of Fanconi anemia","volume":"8","author":"Dave","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clinthera.2026.04.026_fur4","doi-asserted-by":"crossref","first-page":"103060","DOI":"10.1016\/j.transci.2021.103060","article-title":"CRISPR\/Cas9 gene editing for curing sickle cell disease","volume":"60","author":"Park","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clinthera.2026.04.026_fur5","doi-asserted-by":"crossref","unstructured":"Worthington A.K., Borges B., Lum T., et al. In utero lipid nanoparticle delivery achieves robust editing in hematopoietic stem cells. bioRxiv. Published online January 1, 2025:2025.05.12.652147. doi:10.1101\/2025.05.12.652147.","DOI":"10.1101\/2025.05.12.652147"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:18:06Z","timestamp":1781191086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0149291826001451"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.026","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Utero Gene Therapy for Sickle Cell Disease: Current Evidence, Ethical Considerations, and Future Directions\u2014A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}